PUD Flashcards
Indications of Antacid therapy
Mild GORD
Dyspepsia
Reflux oseophagitis
MOA of Antacids
Neutralise gastric acidity
Which are the Antacids
NaHCO3
CaCO3
Al(OH)3
Mg(OH)3
AE of systemic antacids
NaHCO3:
Na and H2O retention=Hypertension
AE of Non-systemic antacids
CaCO3:
Hypercalcaemia, rebound acidosis, belching
Al(OH)3: Constipation
Mg(OH)3: diarhoea
In renal insufficiency, systemic antacids result in
Metabolic alkalosis
In renal insufficiency, non-systemic antacids result in
Toxicity
Caution in Mg(OH)3
renal insufficiency: incr. plasma Mg–>
hypermagnesaemia= mental depression, coma and NV
Caution in Al(OH)3
renal insufficiency: incr. Al–> CNS accumulation=incr. neurotoxicity, encephalopathy
DI in Antacids
Absorb other drugs: digoxin, phenytoin
Chelates other drugs: iron, tetracyclines
Incr. gastric emptying: decr. absorption of digoxin, levadopa
Incr. gastric pH: decr. absorp. of acidic drugs indomethacin, sulphonamides, ketoconazole, itraconazole
Urine alkalinisation: incr. clearance ot tetracyclines, sulphonylureas
Dosing interval requirements in Antacids
4 hrs before or 2 hrs after other drugs
Which are the PPIs
Omeprazole
Esomeprazole
Lansoprazole
Pantoprazole
Rabeprazole
Indications of PPIs
Duodenal & gastric ulcer (stress/NSAID)
GORD
H. Pylori irradication (+ antibiotics)
ZOllinger-Ellison Syndrome
MOA of PPIs
-Irreversibly bind to and inhibit H/K ATPAse pump enzyme of gastric parietal cell
-weak bases=incr. pH=stabilise ulcer clot= decr. bleeding
-inhibit H.pylore urease= prevent ammonia production and expose H.Pylori to acidic conditions
-inhibit gastric mucosal carbonic anhydrase
DOA of PPIs
24-48 hrs
Bioavailability of PPIs
Pantoprazole>lansoprazole>rabeprazole> omeprazole
DI of PPIs
inhibit CYP450:
decr. elimination of diazepam, warfarin, phenytoin
decr. gastric acidity:
decr. absorp. of ketoconazole, itraconazole